Patient-Preferred Trials

After years of innovative research, advanced therapies are dramatically changing the way patients are treated for a wide variety of diseases particularly for patients with rare diseases and orphan indications. New developments in advanced therapy medicinal products (ATMPs) comprising cell and gene therapy products show the potential to modify or even cure severe chronic conditions for which previously no treatment existed. As a consequence, the dynamic market for innovative therapies such as CAR-T, immuno-oncology, and gene and cell-based therapies grows across the globe. Academic institutes and biotech companies are contributing to these developments both in terms of scientific discovery and undertaking clinical trials aiming for regulatory approvals to treat specific patient populations. While we might be in a golden age of medicine due to advancements in ATMPs, innovative clinical research and development remain crucial for getting treatments to patients.

There has been growing interest in Pichia for use in the production of biopharmaceuticals including: SARS CoV2 spike protein and RBD, antibodies and other proteins for medicinal purposes.

Labroots and the Drug Discovery planning committee are pleased to announce its 6th Annual Event in the Drug Discovery & Development Virtual Event Series.

Economic performance could soon replace compliance as the leading quality goal for pharmaceutical companies. According to the 2019 Pharma Quality Outlook Survey, 66% of industry executives named compliance as a top goal, down 10% from last year. Meanwhile, more than one-third (39%) say that economic performance is now their top objective, a 4% increase.Join Sparta System's Steve McCarthy, VP of Digital Innovation, as he discusses key findings from this year's survey, which included responses from 161 professionals.